Breaking News Instant updates and real-time market news.

APHA

Aphria

$6.54

-0.105 (-1.58%)

, NBEV

New Age Beverages

$4.27

0.055 (1.30%)

08:45
07/12/19
07/12
08:45
07/12/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Aphria (APHA) 56.34% +2.45, New Age Beverages (NBEV) 46.79% +0.41, Plug Power (PLUG) 70.46% +0.09, Gerdau (GGB) 0.65% +0.08, Vuzix (VUZI) 153.47% +0.06, Maxar Technologies (MAXR) 4.69% +0.06, Northern Dynasty (NAK) 22.81% +0.06, Twitter (TWTR) 0.30% +0.05, Smartsheet (SMAR) 0.35% +0.03, and Zogenix (ZGNX) 0.43% +0.03.

APHA

Aphria

$6.54

-0.105 (-1.58%)

NBEV

New Age Beverages

$4.27

0.055 (1.30%)

PLUG

Plug Power

$2.29

(0.00%)

GGB

Gerdau

$3.94

-0.1 (-2.48%)

VUZI

Vuzix

$3.06

-0.14 (-4.38%)

MAXR

Maxar Technologies

$9.30

-0.06 (-0.64%)

NAK

Northern Dynasty

$0.49

-0.0105 (-2.10%)

TWTR

Twitter

$37.20

-0.25 (-0.67%)

SMAR

Smartsheet

$52.82

-0.01 (-0.02%)

ZGNX

Zogenix

$47.35

-0.4 (-0.84%)

  • 15

    Jul

  • 26

    Jul

  • 30

    Jul

  • 07

    Aug

APHA Aphria
$6.54

-0.105 (-1.58%)

06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).
05/24/19
JEFF
05/24/19
INITIATION
JEFF
Buy
Jefferies starts Aphria at Buy, says valuation 'not reflective of reality'
Jefferies analyst Owen Bennett initiated coverage of Aphria (APHA) with a Buy rating and C$15 price target. The stock closed yesterday down 33c to $6.41. The analyst says the company scores highly on his "strategic scorecard," or third overall behind only Canopy Growth (CGC) and Aurora Cannabis (ACB). Despite a "strong global outlook," Aphria's valuation is the cheapest across the space, with allegations around inflated assets/insider deals weighing on the shares, Bennett tells investors in a research note. The analyst expects a "significant re-rating" in the shares with "these issues now seemingly cleared up." He points out that the company's questionable relationships have been severed and a special committee review found assets had not been falsely inflated. Bennett believes Aphria continues to execute and that its valuation is "not reflective of reality."
04/16/19
VERF
04/16/19
NO CHANGE
Target $8
VERF
Sell
Use Aphria results as guide and short Tilray shares, says Vertical Group
Vertical Group analyst Gordon Johnson tells investors to use Aphria's (APHA) fiscal Q3 results as a guide and build a short position in Tilray (TLRY). The analyst last week initiated coverage of Tilray with a Sell rating and $8 year-end price target. Despite expectations for growth in Canadian sales due to the growth expectations for the recreational cannabis market, Aphria's kilograms sold fell 22.7% quarter-over-quarter in the quarter reported yesterday, Johnson tells investors in an email to clients. The analyst maintains his negative bias on Tilray following Aphia's results. Shares of Tilray are up 54c to $49.78 in early trading.
05/24/19
05/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Perform at Oppenheimer. 2. CannTrust (CTST) initiated with a Buy at BofA/Merrill. 3. Inseego (INSG) initiated with an Outperform at Cowen. 4. Falcon Minerals (FLMN) initiated with an Outperform at Baird. 5. Aphria (APHA) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NBEV New Age Beverages
$4.27

0.055 (1.30%)

06/10/19
COMP
06/10/19
INITIATION
Target $9
COMP
Buy
New Age Beverages initiated with a Buy at Compass Point
Compass Point analyst Rommel Dionsio started New Age Beverages with a Buy rating and $9 price target.
02/13/19
NORL
02/13/19
NO CHANGE
NORL
Outperform
Northland taking 'conservative' view of New Age Beverages' 2019 results
Northland analyst Mike Grondahl said in a note prior to the open that he believes the fact that new shelf space for larger retailers is generally not available until March/April/May of 2019 presents a challenge to Q$ revenues and earnings for New Age Beverages. Also noting that shipping of new CBD products "remains in limbo due to uncertainty from the FDA," Grondahl lowered his estimates and said he is taking a "conservative look" at 2019 for the company. However, he continues to believe New Age is well positioned for the next few years and keeps an Outperform rating on the shares.
01/07/19
NORL
01/07/19
NO CHANGE
Target $8
NORL
Outperform
New Age Beverages price target raised to $8 from $6 at Northland
Northland analyst Mike Grondahl raised his price target on New Age Beverages to $8 from $6, stating that he sees the important point of the Morinda Holdings acquisition being how well New Age can utilize the 160,000 DTC distribution points to sell other brands in its portfolio, especially its CBD products. He believe New Age's CBD products could ship in the near-term, stating that the Farm Bill passage should make distribution of CBD products "less of a headache." Grondahl maintains an Outperform rating on New Age Beverages shares.
12/04/18
ROTH
12/04/18
NO CHANGE
Target $11
ROTH
Buy
Roth ups New Age Beverages target to $11 on Morinda acquisition
Following this morning's conference call detailing its definitive agreement to acquire Morinda, Roth Capital analyst David Bain raised his price target for New Age Beverages to $11 from $10 and reiterates a Buy rating on the shares. Morinda offers an "instantaneous, unique, world-wide" distribution platform for both New Age's current product portfolio as well as its "upcoming, potentially disruptive" offerings in cannabidiol and health sciences, Bain tells investors in a research note. The analyst adds that his new price target does not take into account announced 2019 revenue synergies from the merger or potential 2020 growth from Morninda.
PLUG Plug Power
$2.29

(0.00%)

01/30/19
01/30/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Synchrony (SYF) upgraded to Buy from Neutral at BofA/Merrill with analyst Kenneth Bruce saying the company's renewal of the Sam's Club partnership, the sale of the Walmart (WMT) portfolio to Capital One (COF) and Walmart's dismissal of the lawsuit against Synchrony "substantially remove many of the key risks" that had been facing the company. 2. Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo. 3. Western New England Bancorp (WNEB) upgraded to Buy from Neutral at Compass Point. 4. Plug Power (PLUG) upgraded to Neutral from Sell at Roth Capital with analyst Craig Irwin citing valuation. 5. Intercept (ICPT) upgraded to Outperform from Market Perform at JMP Securities with analyst Lisa Bayko saying she thinks the REGENERATE trial, which will be reading out this quarter, has "a good shot" to hit on the fibrosis endpoint. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/19
ROTH
01/30/19
UPGRADE
Target $1.3
ROTH
Neutral
Plug Power upgraded to Neutral from Sell at Roth Capital
Roth Capital analyst Craig Irwin upgraded Plug Power to Neutral citing valuation. The share price now appropriately values the key risks and opportunities surrounding the company's operations, Irwin tells investors in a research note. The analyst, however, remains skeptical about Plug Power's second half of 2019 timeline for suggested EBITDA profitability. He maintains a $1.30 price target for the shares.
03/13/19
RILY
03/13/19
INITIATION
Target $3.5
RILY
Buy
Plug Power resumed with a Buy at B. Riley FBR
B. Riley FBR analyst Christopher Van Horn resumed coverage of Plug Power with a Buy rating and $3.50 price target. The rating and price target are unchanged from the firm's prior coverage.
06/11/19
HCWC
06/11/19
NO CHANGE
HCWC
Plug Power acquisition positions it to capitalize, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal maintained a Buy rating and $4 price target on Plug Power following the company's acquisition of lightweight fuel cell company EnergyOr for an undisclosed amount. Dayal said the acquisition puts the company in a position to capitalize on the adoption of last-mile delivery drones, as well as opening additional markets for military unmanned aerial vehicles.
GGB Gerdau
$3.94

-0.1 (-2.48%)

08/16/18
BOFA
08/16/18
INITIATION
BOFA
Buy
Gerdau reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Timna Tanners reinstated Gerdau with a Buy to reflect a positive view on Brazilian construction and SBQ demand.
12/18/18
SCOT
12/18/18
UPGRADE
SCOT
Outperform
Gerdau upgraded to Outperform from Sector Perform at Scotiabank
09/17/18
HSBC
09/17/18
UPGRADE
HSBC
Buy
Gerdau upgraded to Buy from Hold at HSBC
VUZI Vuzix
$3.06

-0.14 (-4.38%)

MAXR Maxar Technologies
$9.30

-0.06 (-0.64%)

03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
CIBC
03/01/19
DOWNGRADE
CIBC
Underperformer
Maxar Technologies downgraded to Underperformer from Neutral at CIBC
03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NAK Northern Dynasty
$0.49

-0.0105 (-2.10%)

11/16/18
CANT
11/16/18
UPGRADE
CANT
Overweight
Northern Dynasty upgraded to Speculative Buy from Hold at Cantor Fitzgerald
Cantor Fitzgerald analyst Mike Kozak upgraded Northern Dynasty to Speculative Buy from Hold and increased his price target to 90c from 40c after the company provided an update on the timing of the Draft Environmental Statement at Pebble. Kozak also cited the election of a new Governor in Alaska and his pro-development view.
TWTR Twitter
$37.20

-0.25 (-0.67%)

06/14/19
LOOP
06/14/19
NO CHANGE
Target $55
LOOP
Buy
Pullback in Twitter stock offers buying opportunity, says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating and $55 price target on Twitter, saying that yesterday's 3% pullback in its stock price following cautious commentary from another sell-side firm offers investors a "buying opportunity". The analyst notes that the company's user engagement story "continues to show solid improvement" with more conversion among users from "casual" to daily. Gould also believes that budget allocations by brand advertisers to Twitter will continue to increase as the industry chases the growth rate of its engagement. The analyst further believes that direct-response advertising will add "another pillar" to Twitter's monetization story.
06/03/19
LOOP
06/03/19
INITIATION
LOOP
Buy
Twitter initiated with a Buy at Loop Capital
06/04/19
06/04/19
INITIATION
Target $55

Buy
Twitter initiated with a Buy at Loop Capital
As previously reported, Loop Capital analyst Alan Gould initiated Twitter with a Buy rating and a price target of $55. The analyst contends that the catch-up in the company's monetization over the past year can continue as user engagement grows further. Gould adds that while that monetization upswing justifies his price target, Twitter also offers "home-run potential", saying that the company is best positioned to capture an opportunity of a "mass-market use case for an interest network."
06/04/19
06/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) was initiated with an Overweight at Barclays and Morgan Stanley, an Outperform at Oppenheimer, Cowen, William Blair, and JMP Securities, a Buy at Canaccord, SunTrust, Deutsche Bank, Loop Capital, Mizuho, BTIG, Needham, and BofA/Merrill, and a Neutral at Citi. 2. Lyft (LYFT) was initiated with a Buy at BTIG, SunTrust, and Citi, a Hold at Loop Capital, and an Equal Weight at Barclays. 3. Alibaba (BABA), JD.com (JD), and Twitter (TWTR) were initiated with a Buy at Loop Capital, while Alphabet (GOOG, GOOGL) was initiated with a Hold. 4. Pfizer (PFE) was resumed with an Overweight at Morgan Stanley. 5. Neon Therapeutics (NTGN) was initiated with a Buy at Mizuho. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SMAR Smartsheet
$52.82

-0.01 (-0.02%)

06/06/19
JEFF
06/06/19
NO CHANGE
Target $52
JEFF
Buy
Smartsheet 'easily exceeded' fiscal Q1 estimates, says Jefferies
Smartsheet last night "easily exceeded" fiscal Q1 estimates across all metrics while maintaining a "consistently high" subscription revenue growth rate of 57%, Jefferies analyst John DiFucci tells investors in a reach note. Further, the company's Q2 guidance was better than expectations other than earnings, though annual earnings guidance was largely maintained, adds the analyst. He believes management's confidence in the business was reflected in the annual revenue guidance. DiFucci keeps a Buy rating on Smartsheet with a $52 price target.
06/06/19
JPMS
06/06/19
NO CHANGE
Target $47
JPMS
Overweight
Smartsheet target raised to $47 on 'strong' Q1 at JPMorgan
JPMorgan analyst Mark Murphy raised his price target for Smartsheet to $47 from $45 saying the company reported "strong" fiscal Q1 results, with outperformance across all key metrics and raising full year revenue and billings guidance. Calculated billings grew 52% year-over-year and came in six percentage points above consensus expectations, Murphy tells investors in a research note. He maintains an Overweight rating on Smartsheet shares.
06/07/19
DADA
06/07/19
NO CHANGE
Target $45
DADA
Neutral
Smartsheet remains 'fairly valued' after 'strong quarter', says DA Davidson
DA Davidson analyst Rishi Jaluria kept his Neutral rating and $45 price target on Smartsheet after its "strong" beat-and-raise Q1 results, saying the quarter saw "continued strength" in subscription revenue and large customer growth. The analyst attributes the 3% afterhours decline in the stock price to below-consensus Q2 profitability guidance that reflected the spending shift from Q1 and the deceleration in domain customer growth. Jaluria adds that Smartsheet has been "remarkably consistent" with subscription growth of 56%-57% over the past 5 quarters but also notes that the stock trades at a premium valuation relative to its peer group.
07/11/19
NEED
07/11/19
NO CHANGE
Target $60
NEED
Buy
Smartsheet price target raised to $60 from $45 at Needham
Needham analyst Scott Berg raised his price target on Smartsheet to $60 and kept his Buy rating after his visit to the company's HQ yesterday, saying the discussions increased his confidence in his belief that the firm can grow its revenues by 40% or more over the next 2 or more years. The analyst contends that the Collaborative Work Management market is still in the early stages and features "little direct competition", adding that Smartsheet's M&A capacity and "robust" product roadmap will allow it to stay ahead of the "less flexible" solutions of the competition.
ZGNX Zogenix
$47.35

-0.4 (-0.84%)

06/27/19
PIPR
06/27/19
NO CHANGE
Target $64
PIPR
Overweight
Zogenix agreement with FDA 'best case scenario,' says Piper Jaffray
The FDA, in a "surprise turn of events," indicated that it agreed with Zogenix's plan to re-submit their Fintepla new drug application without generating new preclinical toxicity data, Piper Jaffray analyst Danielle Brill tells investors in a research note. Although breakthrough therapy status was rescinded due to the recent approvals of two other drugs for Dravet Syndrome, Brill still expects an expedited review and she estimates approval and launch by Q2 of 2020. The analyst views the news as the "best case scenario" for Zogenix. She does not expect the delay to have any meaningful impact on Fintepla's overall commercial potential and reiterates an Overweight rating on the shares with a $64 price target. The stock in afternoon trading is up 21%, or $8.24, to $47.65.
06/28/19
MZHO
06/28/19
NO CHANGE
Target $65
MZHO
Buy
Zogenix price target raised to $65 from $58 at Mizuho
Mizuho analyst Difei Yang raised her price target for Zogenix to $65 from $58 following the FDA's decision to allow a re-submission of the new drug application for Fintepla. The analyst believes a priority review is highly likely and views the FDA's decision as a positive. She reiterates a Buy rating on Zogenix shares.
06/27/19
GUGG
06/27/19
UPGRADE
GUGG
Buy
Zogenix upgraded to Buy from Neutral at Guggenheim
06/27/19
06/27/19
UPGRADE
Target $64

Buy
Zogenix upgraded to Buy Fintepla NDA news at Guggenheim
As previously reported, Guggenheim analyst Yatin Suneja upgraded Zogenix to Buy from Neutral after speaking with management following the news on Fintepla NDA resubmission in Dravet in Q3. The analyst believes the company has a clear understanding with the FDA on potential approval pathway and views the news as the best case scenario. The company also announced the loss of breakthrough designation, which is surprising but in line with FDA policy, he notes, adding however, that it does not change his view on the approvability of the drug and thinks priority review could help with a speedy approval. Suneja also raised his price target on the shares to $64 from $40.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.